Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zubair Afzal

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Journal of Personalized Medicine|July 27, 2024
Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision MedicineMuhammad Zubair Afzal, Linda T Vahdat
Journal of Pharmacy Practice|July 23, 2016
Evaluation of a Pharmacist and Nurse Practitioner Smoking Cessation ProgramZubair Afzal, Elizabeth Pogge, Virginia Boomershine
Journal for Immunotherapy of Cancer|February 14, 2018
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy aloneMuhammad Zubair Afzal, Rodwell Mabaera, Keisuke Shirai
Journal of Thoracic Disease|August 3, 2018
A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancerMuhammad Zubair Afzal, Konstantin Dragnev, Keisuke Shirai
Journal of Thoracic Disease|September 16, 2021
Does denosumab offer survival benefits? -Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitorsYenong Cao, Muhammad Zubair Afzal, Keisuke Shirai
BMJ Case Reports|August 21, 2021
Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanomaYenong Cao, Muhammad Zubair Afzal, Keisuke Shirai
Annals of Translational Medicine|April 30, 2019
An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancerMuhammad Zubair Afzal, Konstantin H Dragnev, Keisuke Shirai
Journal for Immunotherapy of Cancer|July 4, 2018
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanomaMuhammad Zubair Afzal, Rima R Mercado, Keisuke Shirai
BMJ Case Reports|July 14, 2023
Complete response of a large basosquamous carcinoma following treatment with cemiplimab and vismodegibJonathan Pirruccello, Muhammad Zubair Afzal, Mariana Voudouri, et al.
Journal of Cancer Research and Therapeutics|January 25, 2012
Osteonecrosis of jaw with the use of denosumabNaveed Hassan Akhtar, Muhammad Zubair Afzal, Ali Arslan Aftab Ahmed
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Journal of Personalized Medicine|July 27, 2024
Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision MedicineMuhammad Zubair Afzal, Linda T Vahdat
Journal of Pharmacy Practice|July 23, 2016
Evaluation of a Pharmacist and Nurse Practitioner Smoking Cessation ProgramZubair Afzal, Elizabeth Pogge, Virginia Boomershine
Journal for Immunotherapy of Cancer|February 14, 2018
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy aloneMuhammad Zubair Afzal, Rodwell Mabaera, Keisuke Shirai
Journal of Thoracic Disease|August 3, 2018
A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancerMuhammad Zubair Afzal, Konstantin Dragnev, Keisuke Shirai
Journal of Thoracic Disease|September 16, 2021
Does denosumab offer survival benefits? -Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitorsYenong Cao, Muhammad Zubair Afzal, Keisuke Shirai
BMJ Case Reports|August 21, 2021
Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanomaYenong Cao, Muhammad Zubair Afzal, Keisuke Shirai
Annals of Translational Medicine|April 30, 2019
An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancerMuhammad Zubair Afzal, Konstantin H Dragnev, Keisuke Shirai
Journal for Immunotherapy of Cancer|July 4, 2018
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanomaMuhammad Zubair Afzal, Rima R Mercado, Keisuke Shirai
BMJ Case Reports|July 14, 2023
Complete response of a large basosquamous carcinoma following treatment with cemiplimab and vismodegibJonathan Pirruccello, Muhammad Zubair Afzal, Mariana Voudouri, et al.
Journal of Cancer Research and Therapeutics|January 25, 2012
Osteonecrosis of jaw with the use of denosumabNaveed Hassan Akhtar, Muhammad Zubair Afzal, Ali Arslan Aftab Ahmed
Pageof 4